[{"from": "human", "value": "Provide a description of this molecule. [C][C][C][=C][Branch1][#Branch2][C][=C][C][=Branch1][Ring2][=C][Ring1][=Branch1][F][O][C][Ring1][O][C][Branch2][Ring1][N][C][N][C][C][Branch2][Ring1][Ring2][C][C][C][C][=C][Branch1][Ring2][O][Ring1][=Branch1][C][=C][C][=Branch1][Ring2][=C][Ring1][#Branch1][F][O][O]"}, {"from": "gpt", "value": "The molecule is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than [atenolol], [propranolol], or [pindolol]. Nebivolol and other beta blockers are generally not first line therapies as many patients are first treated with thiazide diuretics.  Nebivolol was granted FDA approval on 17 December 2007."}]